http://pharmalicensing.com/rss/ Latest market and business intelligence from the leading publishers worldwide. en-us http://pharmalicensing.com/rss/ http://pharmalicensing.com/images/pharmalicensing_logo.gif 144 Amsterdam, The Netherlands - November 11, 2009 - Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that it has successfully treated... http://pharmalicensing.com/redirs/news_rss//public/news/view/499801/0/9/amt-successful-in-preclinical-treatment-of-dmd http://pharmalicensing.com/redirs/news_rss//public/news/view/499801/0/9/amt-successful-in-preclinical-treatment-of-dmd (PRINCETON, New Jersey, and BOTHELL, Washington, November 10, 2009) - Bristol-Myers Squibb Company (NYSE:BMY) and Alder Biopharmaceuticals, Inc., today announced a global agreement for the... http://pharmalicensing.com/redirs/news_rss//public/news/view/499666/0/9/bristol-myers-squibb-and-alder-biopharmaceuticals-enter-global-agreement-on-rheumatoid-arthritis-biologic http://pharmalicensing.com/redirs/news_rss//public/news/view/499666/0/9/bristol-myers-squibb-and-alder-biopharmaceuticals-enter-global-agreement-on-rheumatoid-arthritis-biologic MONTREAL, November 3, 2009 -- Enobia Pharma announced today the initiation of a Phase 2 clinical study of ENB-0040, a bone-targeted enzyme replacement therapy, under investigation for the treatment... http://pharmalicensing.com/redirs/news_rss//public/news/view/498597/0/9/enobia-pharma-expands-clinical-program-for-enb-0040-a-bone-targeted-enzyme-replacement-therapy-for-hypophosphatasia http://pharmalicensing.com/redirs/news_rss//public/news/view/498597/0/9/enobia-pharma-expands-clinical-program-for-enb-0040-a-bone-targeted-enzyme-replacement-therapy-for-hypophosphatasia Monday 2nd November 2009, London UK & Philadelphia US --GlaxoSmithKline PLC (GSK) and Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that Benlysta(TM) (belimumab) met the primary endpoint... http://pharmalicensing.com/redirs/news_rss//public/news/view/498592/0/9/glaxosmithkline-and-human-genome-sciences-announce-positive-results-in-second-of-two-phase-3-trials-of-benlysta-in-systemic-lupus-erythematosus http://pharmalicensing.com/redirs/news_rss//public/news/view/498592/0/9/glaxosmithkline-and-human-genome-sciences-announce-positive-results-in-second-of-two-phase-3-trials-of-benlysta-in-systemic-lupus-erythematosus Dundee, Scotland, 16 October, 2009: Axis-Shield plc (LSE:ASD, OSE:ASD), the international in vitro diagnostics (IVD) company, today announces that it has received marketing clearance from the US Food... http://pharmalicensing.com/redirs/news_rss//public/news/view/497928/0/9/axis-shield-receives-fda-clearance-for-the-anti-ccp-rheumatoid-arthritis-test-on-abbotts-architect-analyser http://pharmalicensing.com/redirs/news_rss//public/news/view/497928/0/9/axis-shield-receives-fda-clearance-for-the-anti-ccp-rheumatoid-arthritis-test-on-abbotts-architect-analyser SAN DIEGO, CA, October 08, 2009 -- Lpath, Inc. (OTCBB: LPTN), the category leader in lipidomics-based therapeutics, reported positive summary results of its single-dose Phase 1 clinical trial of... http://pharmalicensing.com/redirs/news_rss//public/news/view/498442/0/9/lpaths-isonep-is-well-tolerated-at-all-dose-levels-in-a-phase-1-trial-in-wet-amd-patients http://pharmalicensing.com/redirs/news_rss//public/news/view/498442/0/9/lpaths-isonep-is-well-tolerated-at-all-dose-levels-in-a-phase-1-trial-in-wet-amd-patients